1071842-61-9

Basic information

• Product Name: Cyclopropyl 4-Fluorobenzyl Ketone
• Synonyms: Cyclopropyl 4-Fluorobenzyl Ketone;1-cyclopropyl-2-(4-fluorophenyl)ethanone;1-CYCLOPROPYL-2-(4-FLUOROPHENYL)ETHAN-1-ONE;Prasugrel Impurity 17
• CAS NO: 1071842-61-9
• Molecular Formula: C₁₁H₁₁FO
• Molecular Weight: 178.2028432
• Product Categories: Aromatics, Intermediates, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 1071842-61-9.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: Dichloromethane, DMSO, Ethyl Acetate, Methanol
• CAS DataBase Reference: Cyclopropyl 4-Fluorobenzyl Ketone(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopropyl 4-Fluorobenzyl Ketone(1071842-61-9)
• EPA Substance Registry System: Cyclopropyl 4-Fluorobenzyl Ketone(1071842-61-9)

Safety Data

• Hazardous Substances Data: 1071842-61-9(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

Cyclopropyl 4-Fluorobenzyl Ketone is a cyclopropyl ethanone derivative, used in the preparation of p-Fluoro Prasugrel (F595875).

Upstream product

• 23719-80-4 cyclopropylmagnesium bromide 
• 459-04-1 4-Fluorophenylacetyl chloride 

Downstream Products

• 1607817-42-4 4-cyclopropyl-5-(4-fluorophenyl)pyrimidin-2-amine 
• 1198272-07-9 C₁₆H₁₅FO₅ 
• 1198272-17-1 C₁₃H₁₁FO₃ 
• 1198272-25-1 C₁₇H₁₅FO₅ 
• 1071842-43-7 3-(2-chloroetyhyl)-5-(4-fluorophenyl)-4H-pyran-4-one 

Relevant articles and documents

Small molecule that reverses dexamethasone resistance in t-cell acute lymphoblastic leukemia (T-ALL)

Glucocorticoids are one of the most utilized and effective therapies in treating T-cell acute lymphoblastic leukemia. However, patients often develop resistance to glucocorticoids, rendering these therapies ineffective. We screened 9517 compounds, selected for their lead-like properties, chosen from among 3372615 compounds, against a dexamethasone-resistant T-ALL cell line to identify small molecules that reverse glucocorticoid resistance. We synthesized analogues of the most effective compound, termed J9, from the screen in order to define the scaffolds structure-activity relationship. Active compounds restored sensitivity to glucocorticoids through upregulation of the glucocorticoid receptor. This compound and mechanism may provide a strategy for overcoming glucocorticoid resistance in patients with T-ALL.